nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—kidney cancer—urinary bladder cancer	0.488	1	CtDrD
Sorafenib—RALBP1—Doxorubicin—urinary bladder cancer	0.0533	0.203	CbGbCtD
Sorafenib—CYP2B6—Thiotepa—urinary bladder cancer	0.0192	0.0734	CbGbCtD
Sorafenib—ABCC4—Fluorouracil—urinary bladder cancer	0.0165	0.063	CbGbCtD
Sorafenib—UGT1A1—Etoposide—urinary bladder cancer	0.0135	0.0514	CbGbCtD
Sorafenib—ABCB1—Mitomycin—urinary bladder cancer	0.013	0.0496	CbGbCtD
Sorafenib—ABCC2—Carboplatin—urinary bladder cancer	0.00977	0.0373	CbGbCtD
Sorafenib—ABCC4—Methotrexate—urinary bladder cancer	0.00911	0.0347	CbGbCtD
Sorafenib—ABCG2—Fluorouracil—urinary bladder cancer	0.00888	0.0339	CbGbCtD
Sorafenib—ABCG2—Carboplatin—urinary bladder cancer	0.00883	0.0337	CbGbCtD
Sorafenib—ABCC2—Cisplatin—urinary bladder cancer	0.00835	0.0318	CbGbCtD
Sorafenib—ABCC2—Etoposide—urinary bladder cancer	0.0082	0.0313	CbGbCtD
Sorafenib—ABCG2—Cisplatin—urinary bladder cancer	0.00755	0.0288	CbGbCtD
Sorafenib—ABCG2—Etoposide—urinary bladder cancer	0.00742	0.0283	CbGbCtD
Sorafenib—CYP3A4—Thiotepa—urinary bladder cancer	0.00591	0.0225	CbGbCtD
Sorafenib—ABCC2—Doxorubicin—urinary bladder cancer	0.00559	0.0213	CbGbCtD
Sorafenib—ABCC2—Methotrexate—urinary bladder cancer	0.00542	0.0207	CbGbCtD
Sorafenib—CYP2B6—Cisplatin—urinary bladder cancer	0.00531	0.0202	CbGbCtD
Sorafenib—ABCG2—Doxorubicin—urinary bladder cancer	0.00506	0.0193	CbGbCtD
Sorafenib—ABCG2—Methotrexate—urinary bladder cancer	0.0049	0.0187	CbGbCtD
Sorafenib—CYP2C8—Fluorouracil—urinary bladder cancer	0.00473	0.0181	CbGbCtD
Sorafenib—CYP3A5—Etoposide—urinary bladder cancer	0.00411	0.0157	CbGbCtD
Sorafenib—CYP2C8—Etoposide—urinary bladder cancer	0.00395	0.0151	CbGbCtD
Sorafenib—ABCB1—Gemcitabine—urinary bladder cancer	0.00375	0.0143	CbGbCtD
Sorafenib—CYP1A2—Fluorouracil—urinary bladder cancer	0.00366	0.014	CbGbCtD
Sorafenib—CYP2B6—Doxorubicin—urinary bladder cancer	0.00356	0.0136	CbGbCtD
Sorafenib—CYP2C9—Fluorouracil—urinary bladder cancer	0.0033	0.0126	CbGbCtD
Sorafenib—CYP1A2—Etoposide—urinary bladder cancer	0.00306	0.0117	CbGbCtD
Sorafenib—CYP2C9—Cisplatin—urinary bladder cancer	0.0028	0.0107	CbGbCtD
Sorafenib—ABCB1—Cisplatin—urinary bladder cancer	0.00272	0.0104	CbGbCtD
Sorafenib—ABCB1—Etoposide—urinary bladder cancer	0.00267	0.0102	CbGbCtD
Sorafenib—ABCB1—Doxorubicin—urinary bladder cancer	0.00182	0.00696	CbGbCtD
Sorafenib—ABCB1—Methotrexate—urinary bladder cancer	0.00177	0.00674	CbGbCtD
Sorafenib—PDGFRA—penis—urinary bladder cancer	0.00176	0.025	CbGeAlD
Sorafenib—CYP2D6—Doxorubicin—urinary bladder cancer	0.00172	0.00655	CbGbCtD
Sorafenib—CYP3A4—Etoposide—urinary bladder cancer	0.0016	0.00611	CbGbCtD
Sorafenib—FLT1—umbilical vein—urinary bladder cancer	0.00155	0.022	CbGeAlD
Sorafenib—KDR—umbilical vein—urinary bladder cancer	0.00131	0.0186	CbGeAlD
Sorafenib—UGT1A1—urine—urinary bladder cancer	0.00112	0.0159	CbGeAlD
Sorafenib—CYP3A4—Doxorubicin—urinary bladder cancer	0.00109	0.00417	CbGbCtD
Sorafenib—CDKL3—female reproductive system—urinary bladder cancer	0.001	0.0143	CbGeAlD
Sorafenib—CDKL2—female reproductive system—urinary bladder cancer	0.000916	0.0131	CbGeAlD
Sorafenib—MAPK11—prostate gland—urinary bladder cancer	0.000896	0.0128	CbGeAlD
Sorafenib—CDK7—prostate gland—urinary bladder cancer	0.000882	0.0126	CbGeAlD
Sorafenib—TAOK2—prostate gland—urinary bladder cancer	0.000875	0.0125	CbGeAlD
Sorafenib—MAPK15—female reproductive system—urinary bladder cancer	0.000825	0.0118	CbGeAlD
Sorafenib—EPHA6—prostate gland—urinary bladder cancer	0.000804	0.0115	CbGeAlD
Sorafenib—ZAK—prostate gland—urinary bladder cancer	0.000762	0.0109	CbGeAlD
Sorafenib—HIPK3—prostate gland—urinary bladder cancer	0.000746	0.0106	CbGeAlD
Sorafenib—TIE1—prostate gland—urinary bladder cancer	0.000697	0.00993	CbGeAlD
Sorafenib—BRAF—prostate gland—urinary bladder cancer	0.000668	0.00952	CbGeAlD
Sorafenib—ZAK—seminal vesicle—urinary bladder cancer	0.000645	0.00919	CbGeAlD
Sorafenib—EPHX2—prostate gland—urinary bladder cancer	0.000639	0.0091	CbGeAlD
Sorafenib—CYP2C19—urine—urinary bladder cancer	0.000605	0.00862	CbGeAlD
Sorafenib—CDK7—renal system—urinary bladder cancer	0.000601	0.00856	CbGeAlD
Sorafenib—TAOK2—urethra—urinary bladder cancer	0.000586	0.00835	CbGeAlD
Sorafenib—FLT4—prostate gland—urinary bladder cancer	0.000576	0.00821	CbGeAlD
Sorafenib—FGFR1—prostate gland—urinary bladder cancer	0.000568	0.0081	CbGeAlD
Sorafenib—HIPK4—female reproductive system—urinary bladder cancer	0.000555	0.00791	CbGeAlD
Sorafenib—EPHX2—seminal vesicle—urinary bladder cancer	0.00054	0.0077	CbGeAlD
Sorafenib—MAP3K7—prostate gland—urinary bladder cancer	0.000538	0.00767	CbGeAlD
Sorafenib—MKNK2—prostate gland—urinary bladder cancer	0.000521	0.00743	CbGeAlD
Sorafenib—MKNK1—prostate gland—urinary bladder cancer	0.000515	0.00734	CbGeAlD
Sorafenib—TIE1—epithelium—urinary bladder cancer	0.000512	0.0073	CbGeAlD
Sorafenib—ZAK—urethra—urinary bladder cancer	0.00051	0.00727	CbGeAlD
Sorafenib—RET—prostate gland—urinary bladder cancer	0.000509	0.00725	CbGeAlD
Sorafenib—HIPK3—renal system—urinary bladder cancer	0.000508	0.00724	CbGeAlD
Sorafenib—CYP1A2—urine—urinary bladder cancer	0.000494	0.00704	CbGeAlD
Sorafenib—TIE1—smooth muscle tissue—urinary bladder cancer	0.000494	0.00703	CbGeAlD
Sorafenib—MAPK11—female reproductive system—urinary bladder cancer	0.000489	0.00697	CbGeAlD
Sorafenib—CDK7—female reproductive system—urinary bladder cancer	0.000481	0.00686	CbGeAlD
Sorafenib—AURKC—female reproductive system—urinary bladder cancer	0.000474	0.00675	CbGeAlD
Sorafenib—RALBP1—prostate gland—urinary bladder cancer	0.000471	0.00671	CbGeAlD
Sorafenib—CYP2C9—urine—urinary bladder cancer	0.000469	0.00668	CbGeAlD
Sorafenib—TIE1—urethra—urinary bladder cancer	0.000467	0.00665	CbGeAlD
Sorafenib—MAP3K7—seminal vesicle—urinary bladder cancer	0.000455	0.00648	CbGeAlD
Sorafenib—FLT1—prostate gland—urinary bladder cancer	0.000448	0.00638	CbGeAlD
Sorafenib—RAF1—prostate gland—urinary bladder cancer	0.000445	0.00634	CbGeAlD
Sorafenib—EPHB6—prostate gland—urinary bladder cancer	0.000443	0.00631	CbGeAlD
Sorafenib—MKNK2—seminal vesicle—urinary bladder cancer	0.000441	0.00628	CbGeAlD
Sorafenib—EPHA6—female reproductive system—urinary bladder cancer	0.000439	0.00625	CbGeAlD
Sorafenib—TAOK2—vagina—urinary bladder cancer	0.000432	0.00615	CbGeAlD
Sorafenib—EPHX2—urethra—urinary bladder cancer	0.000428	0.00609	CbGeAlD
Sorafenib—STK10—prostate gland—urinary bladder cancer	0.000424	0.00604	CbGeAlD
Sorafenib—FLT4—epithelium—urinary bladder cancer	0.000423	0.00603	CbGeAlD
Sorafenib—PDGFRA—prostate gland—urinary bladder cancer	0.00042	0.00598	CbGeAlD
Sorafenib—ZAK—female reproductive system—urinary bladder cancer	0.000416	0.00593	CbGeAlD
Sorafenib—CDK7—Idarubicin—Valrubicin—urinary bladder cancer	0.000412	0.166	CbGdCrCtD
Sorafenib—CDK7—Epirubicin—Valrubicin—urinary bladder cancer	0.000412	0.166	CbGdCrCtD
Sorafenib—CDK7—Daunorubicin—Valrubicin—urinary bladder cancer	0.000412	0.166	CbGdCrCtD
Sorafenib—CDK7—Doxorubicin—Valrubicin—urinary bladder cancer	0.000412	0.166	CbGdCrCtD
Sorafenib—HIPK3—female reproductive system—urinary bladder cancer	0.000407	0.0058	CbGeAlD
Sorafenib—UGT1A1—prostate gland—urinary bladder cancer	0.0004	0.00571	CbGeAlD
Sorafenib—MAP3K19—female reproductive system—urinary bladder cancer	0.000399	0.00568	CbGeAlD
Sorafenib—RALBP1—seminal vesicle—urinary bladder cancer	0.000398	0.00568	CbGeAlD
Sorafenib—UGT1A9—renal system—urinary bladder cancer	0.000398	0.00567	CbGeAlD
Sorafenib—MKNK2—epithelium—urinary bladder cancer	0.000383	0.00546	CbGeAlD
Sorafenib—MAP3K7—smooth muscle tissue—urinary bladder cancer	0.000381	0.00543	CbGeAlD
Sorafenib—TIE1—female reproductive system—urinary bladder cancer	0.000381	0.00542	CbGeAlD
Sorafenib—FGFR1—urethra—urinary bladder cancer	0.00038	0.00542	CbGeAlD
Sorafenib—FLT1—seminal vesicle—urinary bladder cancer	0.000379	0.0054	CbGeAlD
Sorafenib—MAP2K5—prostate gland—urinary bladder cancer	0.000379	0.00539	CbGeAlD
Sorafenib—KDR—prostate gland—urinary bladder cancer	0.000379	0.00539	CbGeAlD
Sorafenib—RAF1—seminal vesicle—urinary bladder cancer	0.000377	0.00537	CbGeAlD
Sorafenib—ZAK—vagina—urinary bladder cancer	0.000376	0.00536	CbGeAlD
Sorafenib—EPHB6—seminal vesicle—urinary bladder cancer	0.000374	0.00534	CbGeAlD
Sorafenib—RET—epithelium—urinary bladder cancer	0.000374	0.00532	CbGeAlD
Sorafenib—CSF1R—prostate gland—urinary bladder cancer	0.00037	0.00527	CbGeAlD
Sorafenib—MKNK2—smooth muscle tissue—urinary bladder cancer	0.000369	0.00526	CbGeAlD
Sorafenib—HIPK3—vagina—urinary bladder cancer	0.000368	0.00525	CbGeAlD
Sorafenib—MAP3K7—urethra—urinary bladder cancer	0.00036	0.00513	CbGeAlD
Sorafenib—CYP3A4—urine—urinary bladder cancer	0.000357	0.00509	CbGeAlD
Sorafenib—MKNK2—renal system—urinary bladder cancer	0.000355	0.00506	CbGeAlD
Sorafenib—CYP2D6—urine—urinary bladder cancer	0.000352	0.00501	CbGeAlD
Sorafenib—MKNK2—urethra—urinary bladder cancer	0.000349	0.00497	CbGeAlD
Sorafenib—RET—renal system—urinary bladder cancer	0.000347	0.00494	CbGeAlD
Sorafenib—FLT3—female reproductive system—urinary bladder cancer	0.000346	0.00493	CbGeAlD
Sorafenib—MKNK1—urethra—urinary bladder cancer	0.000345	0.00491	CbGeAlD
Sorafenib—KIT—prostate gland—urinary bladder cancer	0.000336	0.00478	CbGeAlD
Sorafenib—RALBP1—smooth muscle tissue—urinary bladder cancer	0.000333	0.00475	CbGeAlD
Sorafenib—BRAF—vagina—urinary bladder cancer	0.00033	0.0047	CbGeAlD
Sorafenib—FLT1—epithelium—urinary bladder cancer	0.000329	0.00469	CbGeAlD
Sorafenib—PDGFRB—prostate gland—urinary bladder cancer	0.000328	0.00467	CbGeAlD
Sorafenib—RAF1—epithelium—urinary bladder cancer	0.000327	0.00466	CbGeAlD
Sorafenib—RALBP1—renal system—urinary bladder cancer	0.000321	0.00457	CbGeAlD
Sorafenib—MAP2K5—seminal vesicle—urinary bladder cancer	0.00032	0.00456	CbGeAlD
Sorafenib—KDR—seminal vesicle—urinary bladder cancer	0.00032	0.00456	CbGeAlD
Sorafenib—FLT1—smooth muscle tissue—urinary bladder cancer	0.000317	0.00452	CbGeAlD
Sorafenib—EPHX2—vagina—urinary bladder cancer	0.000315	0.00449	CbGeAlD
Sorafenib—RAF1—smooth muscle tissue—urinary bladder cancer	0.000315	0.00449	CbGeAlD
Sorafenib—RALBP1—urethra—urinary bladder cancer	0.000315	0.00449	CbGeAlD
Sorafenib—FLT4—female reproductive system—urinary bladder cancer	0.000314	0.00448	CbGeAlD
Sorafenib—CSF1R—seminal vesicle—urinary bladder cancer	0.000313	0.00445	CbGeAlD
Sorafenib—FLT1—renal system—urinary bladder cancer	0.000305	0.00435	CbGeAlD
Sorafenib—RAF1—renal system—urinary bladder cancer	0.000304	0.00432	CbGeAlD
Sorafenib—FLT1—urethra—urinary bladder cancer	0.0003	0.00427	CbGeAlD
Sorafenib—RAF1—urethra—urinary bladder cancer	0.000298	0.00425	CbGeAlD
Sorafenib—PDGFRA—smooth muscle tissue—urinary bladder cancer	0.000297	0.00423	CbGeAlD
Sorafenib—EPHB6—urethra—urinary bladder cancer	0.000296	0.00422	CbGeAlD
Sorafenib—STK10—renal system—urinary bladder cancer	0.000289	0.00412	CbGeAlD
Sorafenib—MAPK11—lymph node—urinary bladder cancer	0.000286	0.00408	CbGeAlD
Sorafenib—PDGFRA—renal system—urinary bladder cancer	0.000286	0.00408	CbGeAlD
Sorafenib—MKNK2—female reproductive system—urinary bladder cancer	0.000285	0.00406	CbGeAlD
Sorafenib—KIT—seminal vesicle—urinary bladder cancer	0.000284	0.00404	CbGeAlD
Sorafenib—CDK7—lymph node—urinary bladder cancer	0.000282	0.00401	CbGeAlD
Sorafenib—MKNK1—female reproductive system—urinary bladder cancer	0.000281	0.004	CbGeAlD
Sorafenib—FGFR1—vagina—urinary bladder cancer	0.000281	0.004	CbGeAlD
Sorafenib—TAOK2—lymph node—urinary bladder cancer	0.000279	0.00398	CbGeAlD
Sorafenib—KDR—epithelium—urinary bladder cancer	0.000278	0.00396	CbGeAlD
Sorafenib—AURKC—lymph node—urinary bladder cancer	0.000277	0.00395	CbGeAlD
Sorafenib—PDGFRB—seminal vesicle—urinary bladder cancer	0.000277	0.00395	CbGeAlD
Sorafenib—UGT1A1—renal system—urinary bladder cancer	0.000273	0.00389	CbGeAlD
Sorafenib—KDR—smooth muscle tissue—urinary bladder cancer	0.000268	0.00382	CbGeAlD
Sorafenib—MAP3K7—vagina—urinary bladder cancer	0.000266	0.00378	CbGeAlD
Sorafenib—CSF1R—smooth muscle tissue—urinary bladder cancer	0.000262	0.00373	CbGeAlD
Sorafenib—ABCC4—prostate gland—urinary bladder cancer	0.000261	0.00372	CbGeAlD
Sorafenib—KDR—renal system—urinary bladder cancer	0.000258	0.00368	CbGeAlD
Sorafenib—MKNK2—vagina—urinary bladder cancer	0.000257	0.00367	CbGeAlD
Sorafenib—RALBP1—female reproductive system—urinary bladder cancer	0.000257	0.00366	CbGeAlD
Sorafenib—MKNK1—vagina—urinary bladder cancer	0.000254	0.00362	CbGeAlD
Sorafenib—MAP2K5—urethra—urinary bladder cancer	0.000254	0.00361	CbGeAlD
Sorafenib—KDR—urethra—urinary bladder cancer	0.000254	0.00361	CbGeAlD
Sorafenib—ABCC2—prostate gland—urinary bladder cancer	0.000253	0.0036	CbGeAlD
Sorafenib—CSF1R—urethra—urinary bladder cancer	0.000247	0.00353	CbGeAlD
Sorafenib—KIT—epithelium—urinary bladder cancer	0.000247	0.00351	CbGeAlD
Sorafenib—FLT1—female reproductive system—urinary bladder cancer	0.000244	0.00348	CbGeAlD
Sorafenib—ZAK—lymph node—urinary bladder cancer	0.000243	0.00347	CbGeAlD
Sorafenib—RAF1—female reproductive system—urinary bladder cancer	0.000243	0.00346	CbGeAlD
Sorafenib—PDGFRB—epithelium—urinary bladder cancer	0.000241	0.00343	CbGeAlD
Sorafenib—HIPK3—lymph node—urinary bladder cancer	0.000238	0.00339	CbGeAlD
Sorafenib—KIT—smooth muscle tissue—urinary bladder cancer	0.000238	0.00339	CbGeAlD
Sorafenib—RALBP1—vagina—urinary bladder cancer	0.000232	0.00331	CbGeAlD
Sorafenib—PDGFRB—smooth muscle tissue—urinary bladder cancer	0.000232	0.00331	CbGeAlD
Sorafenib—STK10—female reproductive system—urinary bladder cancer	0.000231	0.0033	CbGeAlD
Sorafenib—PDGFRA—female reproductive system—urinary bladder cancer	0.000229	0.00326	CbGeAlD
Sorafenib—KIT—renal system—urinary bladder cancer	0.000229	0.00326	CbGeAlD
Sorafenib—KIT—urethra—urinary bladder cancer	0.000225	0.0032	CbGeAlD
Sorafenib—PDGFRB—renal system—urinary bladder cancer	0.000223	0.00318	CbGeAlD
Sorafenib—TIE1—lymph node—urinary bladder cancer	0.000223	0.00317	CbGeAlD
Sorafenib—FLT1—vagina—urinary bladder cancer	0.000221	0.00315	CbGeAlD
Sorafenib—RAF1—vagina—urinary bladder cancer	0.00022	0.00313	CbGeAlD
Sorafenib—PDGFRB—urethra—urinary bladder cancer	0.000219	0.00313	CbGeAlD
Sorafenib—EPHB6—vagina—urinary bladder cancer	0.000219	0.00311	CbGeAlD
Sorafenib—BRAF—lymph node—urinary bladder cancer	0.000213	0.00304	CbGeAlD
Sorafenib—STK10—vagina—urinary bladder cancer	0.000209	0.00298	CbGeAlD
Sorafenib—PDGFRA—vagina—urinary bladder cancer	0.000207	0.00295	CbGeAlD
Sorafenib—KDR—female reproductive system—urinary bladder cancer	0.000207	0.00294	CbGeAlD
Sorafenib—MAP2K5—female reproductive system—urinary bladder cancer	0.000207	0.00294	CbGeAlD
Sorafenib—EPHX2—lymph node—urinary bladder cancer	0.000204	0.00291	CbGeAlD
Sorafenib—FLT3—lymph node—urinary bladder cancer	0.000203	0.00289	CbGeAlD
Sorafenib—CSF1R—female reproductive system—urinary bladder cancer	0.000202	0.00287	CbGeAlD
Sorafenib—KDR—vagina—urinary bladder cancer	0.000187	0.00266	CbGeAlD
Sorafenib—MAP2K5—vagina—urinary bladder cancer	0.000187	0.00266	CbGeAlD
Sorafenib—ABCG2—prostate gland—urinary bladder cancer	0.000184	0.00262	CbGeAlD
Sorafenib—FLT4—lymph node—urinary bladder cancer	0.000184	0.00262	CbGeAlD
Sorafenib—HTR2B—smooth muscle tissue—urinary bladder cancer	0.000184	0.00262	CbGeAlD
Sorafenib—KIT—female reproductive system—urinary bladder cancer	0.000183	0.00261	CbGeAlD
Sorafenib—CSF1R—vagina—urinary bladder cancer	0.000182	0.0026	CbGeAlD
Sorafenib—FGFR1—lymph node—urinary bladder cancer	0.000181	0.00259	CbGeAlD
Sorafenib—PDGFRB—female reproductive system—urinary bladder cancer	0.000179	0.00255	CbGeAlD
Sorafenib—ABCC4—renal system—urinary bladder cancer	0.000178	0.00253	CbGeAlD
Sorafenib—ABCC2—renal system—urinary bladder cancer	0.000172	0.00245	CbGeAlD
Sorafenib—MAP3K7—lymph node—urinary bladder cancer	0.000172	0.00245	CbGeAlD
Sorafenib—CYP3A5—prostate gland—urinary bladder cancer	0.000171	0.00244	CbGeAlD
Sorafenib—MKNK2—lymph node—urinary bladder cancer	0.000167	0.00237	CbGeAlD
Sorafenib—KIT—vagina—urinary bladder cancer	0.000166	0.00236	CbGeAlD
Sorafenib—MKNK1—lymph node—urinary bladder cancer	0.000164	0.00234	CbGeAlD
Sorafenib—RET—lymph node—urinary bladder cancer	0.000162	0.00231	CbGeAlD
Sorafenib—PDGFRB—vagina—urinary bladder cancer	0.000162	0.00231	CbGeAlD
Sorafenib—ABCG2—seminal vesicle—urinary bladder cancer	0.000156	0.00222	CbGeAlD
Sorafenib—HTR2C—female reproductive system—urinary bladder cancer	0.000151	0.00215	CbGeAlD
Sorafenib—RALBP1—lymph node—urinary bladder cancer	0.00015	0.00214	CbGeAlD
Sorafenib—CDK7—Idarubicin—Epirubicin—urinary bladder cancer	0.000143	0.0579	CbGdCrCtD
Sorafenib—CDK7—Doxorubicin—Epirubicin—urinary bladder cancer	0.000143	0.0579	CbGdCrCtD
Sorafenib—CDK7—Daunorubicin—Epirubicin—urinary bladder cancer	0.000143	0.0579	CbGdCrCtD
Sorafenib—FLT1—lymph node—urinary bladder cancer	0.000143	0.00204	CbGeAlD
Sorafenib—ABCC4—female reproductive system—urinary bladder cancer	0.000142	0.00203	CbGeAlD
Sorafenib—RAF1—lymph node—urinary bladder cancer	0.000142	0.00203	CbGeAlD
Sorafenib—HTR2B—female reproductive system—urinary bladder cancer	0.000142	0.00202	CbGeAlD
Sorafenib—EPHB6—lymph node—urinary bladder cancer	0.000141	0.00201	CbGeAlD
Sorafenib—ABCC2—female reproductive system—urinary bladder cancer	0.000138	0.00196	CbGeAlD
Sorafenib—STK10—lymph node—urinary bladder cancer	0.000135	0.00193	CbGeAlD
Sorafenib—PDGFRA—lymph node—urinary bladder cancer	0.000134	0.00191	CbGeAlD
Sorafenib—CDK7—Epirubicin—Doxorubicin—urinary bladder cancer	0.000133	0.0536	CbGdCrCtD
Sorafenib—CDK7—Idarubicin—Doxorubicin—urinary bladder cancer	0.000133	0.0536	CbGdCrCtD
Sorafenib—CDK7—Daunorubicin—Doxorubicin—urinary bladder cancer	0.000133	0.0536	CbGdCrCtD
Sorafenib—CYP2C8—renal system—urinary bladder cancer	0.000129	0.00184	CbGeAlD
Sorafenib—HTR2B—vagina—urinary bladder cancer	0.000128	0.00183	CbGeAlD
Sorafenib—ABCG2—urethra—urinary bladder cancer	0.000123	0.00176	CbGeAlD
Sorafenib—MAP2K5—lymph node—urinary bladder cancer	0.000121	0.00172	CbGeAlD
Sorafenib—KDR—lymph node—urinary bladder cancer	0.000121	0.00172	CbGeAlD
Sorafenib—CYP1A2—renal system—urinary bladder cancer	0.000121	0.00172	CbGeAlD
Sorafenib—CSF1R—lymph node—urinary bladder cancer	0.000118	0.00168	CbGeAlD
Sorafenib—CYP3A5—renal system—urinary bladder cancer	0.000117	0.00166	CbGeAlD
Sorafenib—CYP2B6—renal system—urinary bladder cancer	0.000116	0.00165	CbGeAlD
Sorafenib—CYP2C19—vagina—urinary bladder cancer	0.000107	0.00153	CbGeAlD
Sorafenib—KIT—lymph node—urinary bladder cancer	0.000107	0.00153	CbGeAlD
Sorafenib—PDGFRB—lymph node—urinary bladder cancer	0.000105	0.00149	CbGeAlD
Sorafenib—CYP2C8—female reproductive system—urinary bladder cancer	0.000103	0.00147	CbGeAlD
Sorafenib—CYP2C8—vagina—urinary bladder cancer	9.35e-05	0.00133	CbGeAlD
Sorafenib—CYP2B6—female reproductive system—urinary bladder cancer	9.28e-05	0.00132	CbGeAlD
Sorafenib—CYP2C9—female reproductive system—urinary bladder cancer	9.19e-05	0.00131	CbGeAlD
Sorafenib—ABCG2—vagina—urinary bladder cancer	9.09e-05	0.0013	CbGeAlD
Sorafenib—ABCB1—prostate gland—urinary bladder cancer	9.08e-05	0.00129	CbGeAlD
Sorafenib—CYP3A4—renal system—urinary bladder cancer	8.75e-05	0.00125	CbGeAlD
Sorafenib—CYP2D6—renal system—urinary bladder cancer	8.61e-05	0.00123	CbGeAlD
Sorafenib—CYP3A5—vagina—urinary bladder cancer	8.44e-05	0.0012	CbGeAlD
Sorafenib—CYP2B6—vagina—urinary bladder cancer	8.39e-05	0.0012	CbGeAlD
Sorafenib—ABCC4—lymph node—urinary bladder cancer	8.33e-05	0.00119	CbGeAlD
Sorafenib—HTR2B—lymph node—urinary bladder cancer	8.29e-05	0.00118	CbGeAlD
Sorafenib—ABCC2—lymph node—urinary bladder cancer	8.07e-05	0.00115	CbGeAlD
Sorafenib—ABCB1—seminal vesicle—urinary bladder cancer	7.68e-05	0.00109	CbGeAlD
Sorafenib—CYP3A4—female reproductive system—urinary bladder cancer	7e-05	0.000998	CbGeAlD
Sorafenib—CYP2D6—female reproductive system—urinary bladder cancer	6.89e-05	0.000982	CbGeAlD
Sorafenib—ABCB1—epithelium—urinary bladder cancer	6.67e-05	0.000951	CbGeAlD
Sorafenib—ABCB1—renal system—urinary bladder cancer	6.19e-05	0.000882	CbGeAlD
Sorafenib—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	6.09e-05	0.000763	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	6.09e-05	0.000762	CcSEcCtD
Sorafenib—ABCB1—urethra—urinary bladder cancer	6.08e-05	0.000867	CbGeAlD
Sorafenib—Body temperature increased—Gemcitabine—urinary bladder cancer	6.06e-05	0.000758	CcSEcCtD
Sorafenib—Renal failure—Methotrexate—urinary bladder cancer	6.04e-05	0.000756	CcSEcCtD
Sorafenib—Neutropenia—Epirubicin—urinary bladder cancer	6.03e-05	0.000755	CcSEcCtD
Sorafenib—Dizziness—Thiotepa—urinary bladder cancer	6.02e-05	0.000754	CcSEcCtD
Sorafenib—Stomatitis—Methotrexate—urinary bladder cancer	5.99e-05	0.00075	CcSEcCtD
Sorafenib—Urticaria—Fluorouracil—urinary bladder cancer	5.98e-05	0.000749	CcSEcCtD
Sorafenib—Dysphagia—Doxorubicin—urinary bladder cancer	5.97e-05	0.000747	CcSEcCtD
Sorafenib—Body temperature increased—Fluorouracil—urinary bladder cancer	5.95e-05	0.000745	CcSEcCtD
Sorafenib—ABCG2—lymph node—urinary bladder cancer	5.88e-05	0.000838	CbGeAlD
Sorafenib—Pancreatitis—Doxorubicin—urinary bladder cancer	5.85e-05	0.000732	CcSEcCtD
Sorafenib—Weight decreased—Epirubicin—urinary bladder cancer	5.83e-05	0.00073	CcSEcCtD
Sorafenib—Dyspnoea—Etoposide—urinary bladder cancer	5.83e-05	0.00073	CcSEcCtD
Sorafenib—Hepatobiliary disease—Methotrexate—urinary bladder cancer	5.81e-05	0.000727	CcSEcCtD
Sorafenib—Epistaxis—Methotrexate—urinary bladder cancer	5.79e-05	0.000725	CcSEcCtD
Sorafenib—Vomiting—Thiotepa—urinary bladder cancer	5.79e-05	0.000725	CcSEcCtD
Sorafenib—Pneumonia—Epirubicin—urinary bladder cancer	5.78e-05	0.000724	CcSEcCtD
Sorafenib—Infestation NOS—Epirubicin—urinary bladder cancer	5.75e-05	0.00072	CcSEcCtD
Sorafenib—Infestation—Epirubicin—urinary bladder cancer	5.75e-05	0.00072	CcSEcCtD
Sorafenib—Rash—Thiotepa—urinary bladder cancer	5.74e-05	0.000719	CcSEcCtD
Sorafenib—Dermatitis—Thiotepa—urinary bladder cancer	5.74e-05	0.000718	CcSEcCtD
Sorafenib—Headache—Thiotepa—urinary bladder cancer	5.7e-05	0.000714	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	5.7e-05	0.000714	CcSEcCtD
Sorafenib—Decreased appetite—Etoposide—urinary bladder cancer	5.69e-05	0.000712	CcSEcCtD
Sorafenib—Renal failure—Epirubicin—urinary bladder cancer	5.65e-05	0.000708	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Etoposide—urinary bladder cancer	5.65e-05	0.000707	CcSEcCtD
Sorafenib—Body temperature increased—Cisplatin—urinary bladder cancer	5.64e-05	0.000707	CcSEcCtD
Sorafenib—Fatigue—Etoposide—urinary bladder cancer	5.64e-05	0.000706	CcSEcCtD
Sorafenib—Neuropathy peripheral—Epirubicin—urinary bladder cancer	5.64e-05	0.000706	CcSEcCtD
Sorafenib—Stomatitis—Epirubicin—urinary bladder cancer	5.6e-05	0.000702	CcSEcCtD
Sorafenib—Jaundice—Epirubicin—urinary bladder cancer	5.6e-05	0.000702	CcSEcCtD
Sorafenib—Pain—Etoposide—urinary bladder cancer	5.59e-05	0.0007	CcSEcCtD
Sorafenib—Constipation—Etoposide—urinary bladder cancer	5.59e-05	0.0007	CcSEcCtD
Sorafenib—Neutropenia—Doxorubicin—urinary bladder cancer	5.58e-05	0.000698	CcSEcCtD
Sorafenib—Hypersensitivity—Fluorouracil—urinary bladder cancer	5.55e-05	0.000695	CcSEcCtD
Sorafenib—Haemoglobin—Methotrexate—urinary bladder cancer	5.54e-05	0.000694	CcSEcCtD
Sorafenib—Haemorrhage—Methotrexate—urinary bladder cancer	5.51e-05	0.00069	CcSEcCtD
Sorafenib—Asthenia—Gemcitabine—urinary bladder cancer	5.5e-05	0.000688	CcSEcCtD
Sorafenib—Urinary tract disorder—Methotrexate—urinary bladder cancer	5.45e-05	0.000682	CcSEcCtD
Sorafenib—Hepatobiliary disease—Epirubicin—urinary bladder cancer	5.44e-05	0.000681	CcSEcCtD
Sorafenib—Epistaxis—Epirubicin—urinary bladder cancer	5.42e-05	0.000679	CcSEcCtD
Sorafenib—Pruritus—Gemcitabine—urinary bladder cancer	5.42e-05	0.000679	CcSEcCtD
Sorafenib—Nausea—Thiotepa—urinary bladder cancer	5.41e-05	0.000677	CcSEcCtD
Sorafenib—Urethral disorder—Methotrexate—urinary bladder cancer	5.41e-05	0.000677	CcSEcCtD
Sorafenib—Weight decreased—Doxorubicin—urinary bladder cancer	5.4e-05	0.000676	CcSEcCtD
Sorafenib—Pneumonia—Doxorubicin—urinary bladder cancer	5.35e-05	0.00067	CcSEcCtD
Sorafenib—Gastrointestinal pain—Etoposide—urinary bladder cancer	5.35e-05	0.00067	CcSEcCtD
Sorafenib—Pruritus—Fluorouracil—urinary bladder cancer	5.33e-05	0.000667	CcSEcCtD
Sorafenib—Infestation NOS—Doxorubicin—urinary bladder cancer	5.32e-05	0.000666	CcSEcCtD
Sorafenib—Infestation—Doxorubicin—urinary bladder cancer	5.32e-05	0.000666	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	5.27e-05	0.00066	CcSEcCtD
Sorafenib—Hypersensitivity—Cisplatin—urinary bladder cancer	5.26e-05	0.000659	CcSEcCtD
Sorafenib—Diarrhoea—Gemcitabine—urinary bladder cancer	5.24e-05	0.000656	CcSEcCtD
Sorafenib—Renal failure—Doxorubicin—urinary bladder cancer	5.23e-05	0.000655	CcSEcCtD
Sorafenib—Erythema multiforme—Methotrexate—urinary bladder cancer	5.21e-05	0.000653	CcSEcCtD
Sorafenib—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	5.21e-05	0.000653	CcSEcCtD
Sorafenib—Urticaria—Etoposide—urinary bladder cancer	5.2e-05	0.000651	CcSEcCtD
Sorafenib—Haemoglobin—Epirubicin—urinary bladder cancer	5.19e-05	0.000649	CcSEcCtD
Sorafenib—Stomatitis—Doxorubicin—urinary bladder cancer	5.19e-05	0.000649	CcSEcCtD
Sorafenib—Jaundice—Doxorubicin—urinary bladder cancer	5.19e-05	0.000649	CcSEcCtD
Sorafenib—Abdominal pain—Etoposide—urinary bladder cancer	5.17e-05	0.000647	CcSEcCtD
Sorafenib—Body temperature increased—Etoposide—urinary bladder cancer	5.17e-05	0.000647	CcSEcCtD
Sorafenib—Haemorrhage—Epirubicin—urinary bladder cancer	5.16e-05	0.000646	CcSEcCtD
Sorafenib—Diarrhoea—Fluorouracil—urinary bladder cancer	5.15e-05	0.000645	CcSEcCtD
Sorafenib—Tinnitus—Methotrexate—urinary bladder cancer	5.14e-05	0.000644	CcSEcCtD
Sorafenib—Asthenia—Cisplatin—urinary bladder cancer	5.12e-05	0.000641	CcSEcCtD
Sorafenib—Cardiac disorder—Methotrexate—urinary bladder cancer	5.12e-05	0.000641	CcSEcCtD
Sorafenib—Urinary tract disorder—Epirubicin—urinary bladder cancer	5.1e-05	0.000638	CcSEcCtD
Sorafenib—Connective tissue disorder—Epirubicin—urinary bladder cancer	5.07e-05	0.000635	CcSEcCtD
Sorafenib—Urethral disorder—Epirubicin—urinary bladder cancer	5.06e-05	0.000633	CcSEcCtD
Sorafenib—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	5.03e-05	0.00063	CcSEcCtD
Sorafenib—Epistaxis—Doxorubicin—urinary bladder cancer	5.02e-05	0.000628	CcSEcCtD
Sorafenib—Angiopathy—Methotrexate—urinary bladder cancer	5e-05	0.000626	CcSEcCtD
Sorafenib—Immune system disorder—Methotrexate—urinary bladder cancer	4.98e-05	0.000624	CcSEcCtD
Sorafenib—Dizziness—Fluorouracil—urinary bladder cancer	4.98e-05	0.000624	CcSEcCtD
Sorafenib—Mediastinal disorder—Methotrexate—urinary bladder cancer	4.97e-05	0.000622	CcSEcCtD
Sorafenib—ABCB1—female reproductive system—urinary bladder cancer	4.96e-05	0.000706	CbGeAlD
Sorafenib—Diarrhoea—Cisplatin—urinary bladder cancer	4.89e-05	0.000612	CcSEcCtD
Sorafenib—Erythema multiforme—Epirubicin—urinary bladder cancer	4.88e-05	0.000611	CcSEcCtD
Sorafenib—Alopecia—Methotrexate—urinary bladder cancer	4.87e-05	0.00061	CcSEcCtD
Sorafenib—Vomiting—Gemcitabine—urinary bladder cancer	4.87e-05	0.00061	CcSEcCtD
Sorafenib—Mental disorder—Methotrexate—urinary bladder cancer	4.83e-05	0.000605	CcSEcCtD
Sorafenib—Rash—Gemcitabine—urinary bladder cancer	4.83e-05	0.000605	CcSEcCtD
Sorafenib—Dermatitis—Gemcitabine—urinary bladder cancer	4.83e-05	0.000604	CcSEcCtD
Sorafenib—Hypersensitivity—Etoposide—urinary bladder cancer	4.82e-05	0.000603	CcSEcCtD
Sorafenib—Tinnitus—Epirubicin—urinary bladder cancer	4.81e-05	0.000602	CcSEcCtD
Sorafenib—Malnutrition—Methotrexate—urinary bladder cancer	4.8e-05	0.000601	CcSEcCtD
Sorafenib—Erythema—Methotrexate—urinary bladder cancer	4.8e-05	0.000601	CcSEcCtD
Sorafenib—Haemoglobin—Doxorubicin—urinary bladder cancer	4.8e-05	0.000601	CcSEcCtD
Sorafenib—Headache—Gemcitabine—urinary bladder cancer	4.8e-05	0.000601	CcSEcCtD
Sorafenib—Flushing—Epirubicin—urinary bladder cancer	4.79e-05	0.0006	CcSEcCtD
Sorafenib—Cardiac disorder—Epirubicin—urinary bladder cancer	4.79e-05	0.0006	CcSEcCtD
Sorafenib—Vomiting—Fluorouracil—urinary bladder cancer	4.79e-05	0.0006	CcSEcCtD
Sorafenib—Haemorrhage—Doxorubicin—urinary bladder cancer	4.78e-05	0.000598	CcSEcCtD
Sorafenib—Rash—Fluorouracil—urinary bladder cancer	4.75e-05	0.000595	CcSEcCtD
Sorafenib—Dermatitis—Fluorouracil—urinary bladder cancer	4.74e-05	0.000594	CcSEcCtD
Sorafenib—Headache—Fluorouracil—urinary bladder cancer	4.72e-05	0.000591	CcSEcCtD
Sorafenib—Urinary tract disorder—Doxorubicin—urinary bladder cancer	4.72e-05	0.00059	CcSEcCtD
Sorafenib—Dysgeusia—Methotrexate—urinary bladder cancer	4.7e-05	0.000589	CcSEcCtD
Sorafenib—Asthenia—Etoposide—urinary bladder cancer	4.69e-05	0.000588	CcSEcCtD
Sorafenib—Connective tissue disorder—Doxorubicin—urinary bladder cancer	4.69e-05	0.000588	CcSEcCtD
Sorafenib—Angiopathy—Epirubicin—urinary bladder cancer	4.68e-05	0.000586	CcSEcCtD
Sorafenib—Urethral disorder—Doxorubicin—urinary bladder cancer	4.68e-05	0.000586	CcSEcCtD
Sorafenib—Immune system disorder—Epirubicin—urinary bladder cancer	4.66e-05	0.000584	CcSEcCtD
Sorafenib—Mediastinal disorder—Epirubicin—urinary bladder cancer	4.65e-05	0.000582	CcSEcCtD
Sorafenib—Pruritus—Etoposide—urinary bladder cancer	4.63e-05	0.000579	CcSEcCtD
Sorafenib—Arrhythmia—Epirubicin—urinary bladder cancer	4.61e-05	0.000577	CcSEcCtD
Sorafenib—Alopecia—Epirubicin—urinary bladder cancer	4.56e-05	0.000571	CcSEcCtD
Sorafenib—Nausea—Gemcitabine—urinary bladder cancer	4.55e-05	0.00057	CcSEcCtD
Sorafenib—Vomiting—Cisplatin—urinary bladder cancer	4.54e-05	0.000568	CcSEcCtD
Sorafenib—Mental disorder—Epirubicin—urinary bladder cancer	4.52e-05	0.000566	CcSEcCtD
Sorafenib—Erythema multiforme—Doxorubicin—urinary bladder cancer	4.52e-05	0.000565	CcSEcCtD
Sorafenib—Rash—Cisplatin—urinary bladder cancer	4.5e-05	0.000564	CcSEcCtD
Sorafenib—Dermatitis—Cisplatin—urinary bladder cancer	4.5e-05	0.000563	CcSEcCtD
Sorafenib—Erythema—Epirubicin—urinary bladder cancer	4.49e-05	0.000563	CcSEcCtD
Sorafenib—Malnutrition—Epirubicin—urinary bladder cancer	4.49e-05	0.000563	CcSEcCtD
Sorafenib—ABCB1—vagina—urinary bladder cancer	4.48e-05	0.000639	CbGeAlD
Sorafenib—Diarrhoea—Etoposide—urinary bladder cancer	4.48e-05	0.00056	CcSEcCtD
Sorafenib—Nausea—Fluorouracil—urinary bladder cancer	4.47e-05	0.00056	CcSEcCtD
Sorafenib—Tinnitus—Doxorubicin—urinary bladder cancer	4.45e-05	0.000557	CcSEcCtD
Sorafenib—Anaemia—Methotrexate—urinary bladder cancer	4.44e-05	0.000556	CcSEcCtD
Sorafenib—Flushing—Doxorubicin—urinary bladder cancer	4.43e-05	0.000555	CcSEcCtD
Sorafenib—Cardiac disorder—Doxorubicin—urinary bladder cancer	4.43e-05	0.000555	CcSEcCtD
Sorafenib—Dysgeusia—Epirubicin—urinary bladder cancer	4.4e-05	0.000551	CcSEcCtD
Sorafenib—Angiopathy—Doxorubicin—urinary bladder cancer	4.33e-05	0.000542	CcSEcCtD
Sorafenib—Dizziness—Etoposide—urinary bladder cancer	4.33e-05	0.000542	CcSEcCtD
Sorafenib—Muscle spasms—Epirubicin—urinary bladder cancer	4.32e-05	0.000541	CcSEcCtD
Sorafenib—Immune system disorder—Doxorubicin—urinary bladder cancer	4.31e-05	0.00054	CcSEcCtD
Sorafenib—Mediastinal disorder—Doxorubicin—urinary bladder cancer	4.3e-05	0.000539	CcSEcCtD
Sorafenib—Leukopenia—Methotrexate—urinary bladder cancer	4.3e-05	0.000538	CcSEcCtD
Sorafenib—Arrhythmia—Doxorubicin—urinary bladder cancer	4.27e-05	0.000534	CcSEcCtD
Sorafenib—Nausea—Cisplatin—urinary bladder cancer	4.24e-05	0.000531	CcSEcCtD
Sorafenib—Alopecia—Doxorubicin—urinary bladder cancer	4.22e-05	0.000528	CcSEcCtD
Sorafenib—Cough—Methotrexate—urinary bladder cancer	4.19e-05	0.000525	CcSEcCtD
Sorafenib—Mental disorder—Doxorubicin—urinary bladder cancer	4.18e-05	0.000524	CcSEcCtD
Sorafenib—Vomiting—Etoposide—urinary bladder cancer	4.16e-05	0.000521	CcSEcCtD
Sorafenib—Erythema—Doxorubicin—urinary bladder cancer	4.16e-05	0.00052	CcSEcCtD
Sorafenib—Malnutrition—Doxorubicin—urinary bladder cancer	4.16e-05	0.00052	CcSEcCtD
Sorafenib—Anaemia—Epirubicin—urinary bladder cancer	4.15e-05	0.00052	CcSEcCtD
Sorafenib—Rash—Etoposide—urinary bladder cancer	4.12e-05	0.000516	CcSEcCtD
Sorafenib—Dermatitis—Etoposide—urinary bladder cancer	4.12e-05	0.000516	CcSEcCtD
Sorafenib—Headache—Etoposide—urinary bladder cancer	4.1e-05	0.000513	CcSEcCtD
Sorafenib—Arthralgia—Methotrexate—urinary bladder cancer	4.09e-05	0.000512	CcSEcCtD
Sorafenib—Myalgia—Methotrexate—urinary bladder cancer	4.09e-05	0.000512	CcSEcCtD
Sorafenib—Dysgeusia—Doxorubicin—urinary bladder cancer	4.07e-05	0.00051	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	4.06e-05	0.000508	CcSEcCtD
Sorafenib—Syncope—Epirubicin—urinary bladder cancer	4.03e-05	0.000504	CcSEcCtD
Sorafenib—Leukopenia—Epirubicin—urinary bladder cancer	4.02e-05	0.000504	CcSEcCtD
Sorafenib—Muscle spasms—Doxorubicin—urinary bladder cancer	4e-05	0.0005	CcSEcCtD
Sorafenib—Loss of consciousness—Epirubicin—urinary bladder cancer	3.95e-05	0.000494	CcSEcCtD
Sorafenib—Cough—Epirubicin—urinary bladder cancer	3.92e-05	0.000491	CcSEcCtD
Sorafenib—Anaphylactic shock—Methotrexate—urinary bladder cancer	3.92e-05	0.000491	CcSEcCtD
Sorafenib—Infection—Methotrexate—urinary bladder cancer	3.89e-05	0.000487	CcSEcCtD
Sorafenib—Nausea—Etoposide—urinary bladder cancer	3.89e-05	0.000486	CcSEcCtD
Sorafenib—Hypertension—Epirubicin—urinary bladder cancer	3.88e-05	0.000486	CcSEcCtD
Sorafenib—Nervous system disorder—Methotrexate—urinary bladder cancer	3.84e-05	0.000481	CcSEcCtD
Sorafenib—Anaemia—Doxorubicin—urinary bladder cancer	3.84e-05	0.000481	CcSEcCtD
Sorafenib—Thrombocytopenia—Methotrexate—urinary bladder cancer	3.84e-05	0.00048	CcSEcCtD
Sorafenib—Arthralgia—Epirubicin—urinary bladder cancer	3.82e-05	0.000479	CcSEcCtD
Sorafenib—Myalgia—Epirubicin—urinary bladder cancer	3.82e-05	0.000479	CcSEcCtD
Sorafenib—Skin disorder—Methotrexate—urinary bladder cancer	3.81e-05	0.000476	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	3.8e-05	0.000476	CcSEcCtD
Sorafenib—Dry mouth—Epirubicin—urinary bladder cancer	3.74e-05	0.000468	CcSEcCtD
Sorafenib—Anorexia—Methotrexate—urinary bladder cancer	3.73e-05	0.000468	CcSEcCtD
Sorafenib—Syncope—Doxorubicin—urinary bladder cancer	3.73e-05	0.000467	CcSEcCtD
Sorafenib—Leukopenia—Doxorubicin—urinary bladder cancer	3.72e-05	0.000466	CcSEcCtD
Sorafenib—Anaphylactic shock—Epirubicin—urinary bladder cancer	3.67e-05	0.000459	CcSEcCtD
Sorafenib—Loss of consciousness—Doxorubicin—urinary bladder cancer	3.65e-05	0.000457	CcSEcCtD
Sorafenib—Infection—Epirubicin—urinary bladder cancer	3.64e-05	0.000456	CcSEcCtD
Sorafenib—Cough—Doxorubicin—urinary bladder cancer	3.63e-05	0.000454	CcSEcCtD
Sorafenib—Shock—Epirubicin—urinary bladder cancer	3.61e-05	0.000452	CcSEcCtD
Sorafenib—Nervous system disorder—Epirubicin—urinary bladder cancer	3.6e-05	0.00045	CcSEcCtD
Sorafenib—Thrombocytopenia—Epirubicin—urinary bladder cancer	3.59e-05	0.000449	CcSEcCtD
Sorafenib—Hypertension—Doxorubicin—urinary bladder cancer	3.59e-05	0.000449	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	3.57e-05	0.000447	CcSEcCtD
Sorafenib—Skin disorder—Epirubicin—urinary bladder cancer	3.56e-05	0.000446	CcSEcCtD
Sorafenib—Arthralgia—Doxorubicin—urinary bladder cancer	3.54e-05	0.000443	CcSEcCtD
Sorafenib—Myalgia—Doxorubicin—urinary bladder cancer	3.54e-05	0.000443	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	3.51e-05	0.00044	CcSEcCtD
Sorafenib—Anorexia—Epirubicin—urinary bladder cancer	3.5e-05	0.000438	CcSEcCtD
Sorafenib—Dyspnoea—Methotrexate—urinary bladder cancer	3.49e-05	0.000437	CcSEcCtD
Sorafenib—Dry mouth—Doxorubicin—urinary bladder cancer	3.46e-05	0.000433	CcSEcCtD
Sorafenib—Dyspepsia—Methotrexate—urinary bladder cancer	3.45e-05	0.000432	CcSEcCtD
Sorafenib—Decreased appetite—Methotrexate—urinary bladder cancer	3.41e-05	0.000426	CcSEcCtD
Sorafenib—Anaphylactic shock—Doxorubicin—urinary bladder cancer	3.39e-05	0.000425	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	3.38e-05	0.000424	CcSEcCtD
Sorafenib—Fatigue—Methotrexate—urinary bladder cancer	3.38e-05	0.000423	CcSEcCtD
Sorafenib—Infection—Doxorubicin—urinary bladder cancer	3.37e-05	0.000422	CcSEcCtD
Sorafenib—Pain—Methotrexate—urinary bladder cancer	3.35e-05	0.00042	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	3.34e-05	0.000418	CcSEcCtD
Sorafenib—Shock—Doxorubicin—urinary bladder cancer	3.34e-05	0.000418	CcSEcCtD
Sorafenib—Nervous system disorder—Doxorubicin—urinary bladder cancer	3.33e-05	0.000417	CcSEcCtD
Sorafenib—Thrombocytopenia—Doxorubicin—urinary bladder cancer	3.32e-05	0.000416	CcSEcCtD
Sorafenib—Skin disorder—Doxorubicin—urinary bladder cancer	3.3e-05	0.000413	CcSEcCtD
Sorafenib—Dyspnoea—Epirubicin—urinary bladder cancer	3.27e-05	0.000409	CcSEcCtD
Sorafenib—Anorexia—Doxorubicin—urinary bladder cancer	3.23e-05	0.000405	CcSEcCtD
Sorafenib—Dyspepsia—Epirubicin—urinary bladder cancer	3.23e-05	0.000404	CcSEcCtD
Sorafenib—Gastrointestinal pain—Methotrexate—urinary bladder cancer	3.2e-05	0.000401	CcSEcCtD
Sorafenib—Decreased appetite—Epirubicin—urinary bladder cancer	3.19e-05	0.000399	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	3.17e-05	0.000396	CcSEcCtD
Sorafenib—Fatigue—Epirubicin—urinary bladder cancer	3.16e-05	0.000396	CcSEcCtD
Sorafenib—Pain—Epirubicin—urinary bladder cancer	3.14e-05	0.000393	CcSEcCtD
Sorafenib—Constipation—Epirubicin—urinary bladder cancer	3.14e-05	0.000393	CcSEcCtD
Sorafenib—Urticaria—Methotrexate—urinary bladder cancer	3.11e-05	0.00039	CcSEcCtD
Sorafenib—Abdominal pain—Methotrexate—urinary bladder cancer	3.1e-05	0.000388	CcSEcCtD
Sorafenib—Body temperature increased—Methotrexate—urinary bladder cancer	3.1e-05	0.000388	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	3.09e-05	0.000387	CcSEcCtD
Sorafenib—Dyspnoea—Doxorubicin—urinary bladder cancer	3.02e-05	0.000379	CcSEcCtD
Sorafenib—Gastrointestinal pain—Epirubicin—urinary bladder cancer	3e-05	0.000375	CcSEcCtD
Sorafenib—Dyspepsia—Doxorubicin—urinary bladder cancer	2.99e-05	0.000374	CcSEcCtD
Sorafenib—Decreased appetite—Doxorubicin—urinary bladder cancer	2.95e-05	0.000369	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	2.93e-05	0.000367	CcSEcCtD
Sorafenib—Fatigue—Doxorubicin—urinary bladder cancer	2.92e-05	0.000366	CcSEcCtD
Sorafenib—Urticaria—Epirubicin—urinary bladder cancer	2.91e-05	0.000365	CcSEcCtD
Sorafenib—Constipation—Doxorubicin—urinary bladder cancer	2.9e-05	0.000363	CcSEcCtD
Sorafenib—Pain—Doxorubicin—urinary bladder cancer	2.9e-05	0.000363	CcSEcCtD
Sorafenib—ABCB1—lymph node—urinary bladder cancer	2.9e-05	0.000413	CbGeAlD
Sorafenib—Abdominal pain—Epirubicin—urinary bladder cancer	2.9e-05	0.000363	CcSEcCtD
Sorafenib—Body temperature increased—Epirubicin—urinary bladder cancer	2.9e-05	0.000363	CcSEcCtD
Sorafenib—Hypersensitivity—Methotrexate—urinary bladder cancer	2.89e-05	0.000361	CcSEcCtD
Sorafenib—Asthenia—Methotrexate—urinary bladder cancer	2.81e-05	0.000352	CcSEcCtD
Sorafenib—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	2.77e-05	0.000347	CcSEcCtD
Sorafenib—Pruritus—Methotrexate—urinary bladder cancer	2.77e-05	0.000347	CcSEcCtD
Sorafenib—Hypersensitivity—Epirubicin—urinary bladder cancer	2.7e-05	0.000338	CcSEcCtD
Sorafenib—Urticaria—Doxorubicin—urinary bladder cancer	2.7e-05	0.000337	CcSEcCtD
Sorafenib—Body temperature increased—Doxorubicin—urinary bladder cancer	2.68e-05	0.000336	CcSEcCtD
Sorafenib—Abdominal pain—Doxorubicin—urinary bladder cancer	2.68e-05	0.000336	CcSEcCtD
Sorafenib—Diarrhoea—Methotrexate—urinary bladder cancer	2.68e-05	0.000336	CcSEcCtD
Sorafenib—Asthenia—Epirubicin—urinary bladder cancer	2.63e-05	0.000329	CcSEcCtD
Sorafenib—Pruritus—Epirubicin—urinary bladder cancer	2.59e-05	0.000325	CcSEcCtD
Sorafenib—Dizziness—Methotrexate—urinary bladder cancer	2.59e-05	0.000324	CcSEcCtD
Sorafenib—Diarrhoea—Epirubicin—urinary bladder cancer	2.51e-05	0.000314	CcSEcCtD
Sorafenib—Hypersensitivity—Doxorubicin—urinary bladder cancer	2.5e-05	0.000313	CcSEcCtD
Sorafenib—Vomiting—Methotrexate—urinary bladder cancer	2.49e-05	0.000312	CcSEcCtD
Sorafenib—Rash—Methotrexate—urinary bladder cancer	2.47e-05	0.000309	CcSEcCtD
Sorafenib—Dermatitis—Methotrexate—urinary bladder cancer	2.47e-05	0.000309	CcSEcCtD
Sorafenib—Headache—Methotrexate—urinary bladder cancer	2.45e-05	0.000307	CcSEcCtD
Sorafenib—Asthenia—Doxorubicin—urinary bladder cancer	2.43e-05	0.000305	CcSEcCtD
Sorafenib—Dizziness—Epirubicin—urinary bladder cancer	2.42e-05	0.000304	CcSEcCtD
Sorafenib—Pruritus—Doxorubicin—urinary bladder cancer	2.4e-05	0.000301	CcSEcCtD
Sorafenib—Vomiting—Epirubicin—urinary bladder cancer	2.33e-05	0.000292	CcSEcCtD
Sorafenib—Nausea—Methotrexate—urinary bladder cancer	2.33e-05	0.000291	CcSEcCtD
Sorafenib—Diarrhoea—Doxorubicin—urinary bladder cancer	2.32e-05	0.000291	CcSEcCtD
Sorafenib—Rash—Epirubicin—urinary bladder cancer	2.31e-05	0.000289	CcSEcCtD
Sorafenib—Dermatitis—Epirubicin—urinary bladder cancer	2.31e-05	0.000289	CcSEcCtD
Sorafenib—Headache—Epirubicin—urinary bladder cancer	2.3e-05	0.000288	CcSEcCtD
Sorafenib—Dizziness—Doxorubicin—urinary bladder cancer	2.24e-05	0.000281	CcSEcCtD
Sorafenib—Nausea—Epirubicin—urinary bladder cancer	2.18e-05	0.000273	CcSEcCtD
Sorafenib—Vomiting—Doxorubicin—urinary bladder cancer	2.16e-05	0.00027	CcSEcCtD
Sorafenib—Rash—Doxorubicin—urinary bladder cancer	2.14e-05	0.000268	CcSEcCtD
Sorafenib—Dermatitis—Doxorubicin—urinary bladder cancer	2.14e-05	0.000268	CcSEcCtD
Sorafenib—Headache—Doxorubicin—urinary bladder cancer	2.13e-05	0.000266	CcSEcCtD
Sorafenib—Nausea—Doxorubicin—urinary bladder cancer	2.02e-05	0.000252	CcSEcCtD
Sorafenib—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	1.49e-06	1.54e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	1.49e-06	1.54e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—ERBB2—urinary bladder cancer	1.49e-06	1.54e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—PTEN—urinary bladder cancer	1.49e-06	1.53e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—PTEN—urinary bladder cancer	1.49e-06	1.53e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—KRAS—urinary bladder cancer	1.48e-06	1.52e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—EGFR—urinary bladder cancer	1.47e-06	1.52e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—KRAS—urinary bladder cancer	1.47e-06	1.52e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.47e-06	1.51e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CCND1—urinary bladder cancer	1.46e-06	1.51e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CCND1—urinary bladder cancer	1.46e-06	1.51e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	1.45e-06	1.49e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—RHOA—urinary bladder cancer	1.43e-06	1.48e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—GPX1—urinary bladder cancer	1.43e-06	1.47e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—HRAS—urinary bladder cancer	1.43e-06	1.47e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—EGFR—urinary bladder cancer	1.42e-06	1.47e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—HRAS—urinary bladder cancer	1.42e-06	1.47e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MMP9—urinary bladder cancer	1.42e-06	1.47e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—ERBB2—urinary bladder cancer	1.42e-06	1.46e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—EP300—urinary bladder cancer	1.42e-06	1.46e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—EP300—urinary bladder cancer	1.42e-06	1.46e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MMP9—urinary bladder cancer	1.42e-06	1.46e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.42e-06	1.46e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—PTEN—urinary bladder cancer	1.41e-06	1.46e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.41e-06	1.46e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CDKN1A—urinary bladder cancer	1.41e-06	1.46e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CXCL8—urinary bladder cancer	1.41e-06	1.46e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—PTEN—urinary bladder cancer	1.41e-06	1.45e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	1.4e-06	1.44e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.4e-06	1.44e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.4e-06	1.44e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—KRAS—urinary bladder cancer	1.39e-06	1.44e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PTEN—urinary bladder cancer	1.39e-06	1.43e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PTEN—urinary bladder cancer	1.39e-06	1.43e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—HRAS—urinary bladder cancer	1.39e-06	1.43e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—SRC—urinary bladder cancer	1.38e-06	1.42e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—SRC—urinary bladder cancer	1.38e-06	1.42e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MYC—urinary bladder cancer	1.37e-06	1.41e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CREBBP—urinary bladder cancer	1.37e-06	1.41e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MYC—urinary bladder cancer	1.36e-06	1.4e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PTGS2—urinary bladder cancer	1.35e-06	1.4e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—NQO1—urinary bladder cancer	1.35e-06	1.39e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IGF1—urinary bladder cancer	1.35e-06	1.39e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL2—urinary bladder cancer	1.35e-06	1.39e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—EP300—urinary bladder cancer	1.35e-06	1.39e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CXCL8—urinary bladder cancer	1.35e-06	1.39e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—TYMS—urinary bladder cancer	1.35e-06	1.39e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TP53—urinary bladder cancer	1.35e-06	1.39e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—EGFR—urinary bladder cancer	1.34e-06	1.39e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—EP300—urinary bladder cancer	1.34e-06	1.39e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—KRAS—urinary bladder cancer	1.34e-06	1.39e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—MYC—urinary bladder cancer	1.34e-06	1.38e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—EGFR—urinary bladder cancer	1.34e-06	1.38e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PTGS2—urinary bladder cancer	1.34e-06	1.38e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.34e-06	1.38e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—HRAS—urinary bladder cancer	1.34e-06	1.38e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	1.33e-06	1.37e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	1.33e-06	1.37e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	1.33e-06	1.37e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—EGFR—urinary bladder cancer	1.33e-06	1.37e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—ERBB2—urinary bladder cancer	1.33e-06	1.37e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—EP300—urinary bladder cancer	1.33e-06	1.37e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—EP300—urinary bladder cancer	1.33e-06	1.37e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	1.32e-06	1.36e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—HRAS—urinary bladder cancer	1.32e-06	1.36e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	1.32e-06	1.36e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CCND1—urinary bladder cancer	1.32e-06	1.36e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—EGFR—urinary bladder cancer	1.31e-06	1.35e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—HRAS—urinary bladder cancer	1.31e-06	1.35e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.31e-06	1.35e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.31e-06	1.35e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TP53—urinary bladder cancer	1.31e-06	1.35e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—SRC—urinary bladder cancer	1.31e-06	1.35e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—SRC—urinary bladder cancer	1.31e-06	1.35e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.3e-06	1.34e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.3e-06	1.34e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.3e-06	1.33e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.3e-06	1.33e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL2—urinary bladder cancer	1.29e-06	1.33e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—HRAS—urinary bladder cancer	1.29e-06	1.33e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—HRAS—urinary bladder cancer	1.28e-06	1.32e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MMP9—urinary bladder cancer	1.28e-06	1.32e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.28e-06	1.32e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GPX1—urinary bladder cancer	1.27e-06	1.31e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CDKN1A—urinary bladder cancer	1.27e-06	1.31e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—KRAS—urinary bladder cancer	1.27e-06	1.31e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—PTEN—urinary bladder cancer	1.27e-06	1.31e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—KRAS—urinary bladder cancer	1.27e-06	1.31e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PPARG—urinary bladder cancer	1.26e-06	1.3e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CXCL8—urinary bladder cancer	1.26e-06	1.3e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—KRAS—urinary bladder cancer	1.26e-06	1.29e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.26e-06	1.29e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CCND1—urinary bladder cancer	1.26e-06	1.29e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—HRAS—urinary bladder cancer	1.25e-06	1.29e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	1.25e-06	1.29e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—HRAS—urinary bladder cancer	1.25e-06	1.29e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.24e-06	1.28e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—KRAS—urinary bladder cancer	1.24e-06	1.28e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—TYMS—urinary bladder cancer	1.24e-06	1.28e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—RHOA—urinary bladder cancer	1.24e-06	1.28e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MYC—urinary bladder cancer	1.24e-06	1.28e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MYC—urinary bladder cancer	1.24e-06	1.28e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PPARG—urinary bladder cancer	1.23e-06	1.27e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—TYMS—urinary bladder cancer	1.23e-06	1.26e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	1.22e-06	1.26e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	1.22e-06	1.26e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.22e-06	1.26e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MMP9—urinary bladder cancer	1.22e-06	1.26e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CDKN1A—urinary bladder cancer	1.21e-06	1.25e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	1.21e-06	1.25e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	1.21e-06	1.25e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—CREBBP—urinary bladder cancer	1.21e-06	1.25e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—EP300—urinary bladder cancer	1.21e-06	1.25e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—PTEN—urinary bladder cancer	1.21e-06	1.25e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—EGFR—urinary bladder cancer	1.21e-06	1.25e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—EGFR—urinary bladder cancer	1.21e-06	1.25e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL2—urinary bladder cancer	1.2e-06	1.24e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	1.18e-06	1.22e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—HRAS—urinary bladder cancer	1.18e-06	1.22e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PTEN—urinary bladder cancer	1.18e-06	1.22e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—SRC—urinary bladder cancer	1.18e-06	1.21e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	1.18e-06	1.21e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MYC—urinary bladder cancer	1.17e-06	1.21e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CCND1—urinary bladder cancer	1.17e-06	1.21e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GPX1—urinary bladder cancer	1.17e-06	1.21e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MYC—urinary bladder cancer	1.17e-06	1.21e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PTEN—urinary bladder cancer	1.17e-06	1.21e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GPX1—urinary bladder cancer	1.16e-06	1.2e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—EP300—urinary bladder cancer	1.16e-06	1.19e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	1.15e-06	1.19e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—EGFR—urinary bladder cancer	1.15e-06	1.18e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.15e-06	1.18e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—EGFR—urinary bladder cancer	1.15e-06	1.18e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—ERBB2—urinary bladder cancer	1.15e-06	1.18e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.14e-06	1.18e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—KRAS—urinary bladder cancer	1.14e-06	1.18e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—KRAS—urinary bladder cancer	1.14e-06	1.18e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—HRAS—urinary bladder cancer	1.14e-06	1.18e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	1.14e-06	1.18e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MMP9—urinary bladder cancer	1.14e-06	1.17e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.13e-06	1.17e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PTEN—urinary bladder cancer	1.13e-06	1.17e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	1.13e-06	1.16e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TP53—urinary bladder cancer	1.13e-06	1.16e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—EP300—urinary bladder cancer	1.13e-06	1.16e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—SRC—urinary bladder cancer	1.12e-06	1.16e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TP53—urinary bladder cancer	1.12e-06	1.15e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—EP300—urinary bladder cancer	1.12e-06	1.15e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.09e-06	1.12e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CXCL8—urinary bladder cancer	1.09e-06	1.12e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—KRAS—urinary bladder cancer	1.09e-06	1.12e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—KRAS—urinary bladder cancer	1.08e-06	1.12e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	1.08e-06	1.11e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—HRAS—urinary bladder cancer	1.08e-06	1.11e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—EP300—urinary bladder cancer	1.08e-06	1.11e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—HRAS—urinary bladder cancer	1.08e-06	1.11e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	1.07e-06	1.1e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PPARG—urinary bladder cancer	1.07e-06	1.1e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—HRAS—urinary bladder cancer	1.07e-06	1.1e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MYC—urinary bladder cancer	1.06e-06	1.09e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—HRAS—urinary bladder cancer	1.06e-06	1.09e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—SRC—urinary bladder cancer	1.05e-06	1.08e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—TYMS—urinary bladder cancer	1.05e-06	1.08e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.04e-06	1.08e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL2—urinary bladder cancer	1.04e-06	1.07e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	1.04e-06	1.07e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	1.04e-06	1.07e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—EGFR—urinary bladder cancer	1.03e-06	1.06e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	1.03e-06	1.06e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TP53—urinary bladder cancer	1.02e-06	1.05e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TP53—urinary bladder cancer	1.02e-06	1.05e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCND1—urinary bladder cancer	1.01e-06	1.04e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MYC—urinary bladder cancer	1.01e-06	1.04e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GPX1—urinary bladder cancer	9.93e-07	1.02e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTGS2—urinary bladder cancer	9.93e-07	1.02e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—EGFR—urinary bladder cancer	9.85e-07	1.01e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MMP9—urinary bladder cancer	9.83e-07	1.01e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CDKN1A—urinary bladder cancer	9.79e-07	1.01e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PTEN—urinary bladder cancer	9.77e-07	1.01e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—KRAS—urinary bladder cancer	9.75e-07	1.01e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	9.75e-07	1e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—HRAS—urinary bladder cancer	9.72e-07	1e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—HRAS—urinary bladder cancer	9.72e-07	1e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	9.7e-07	1e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TP53—urinary bladder cancer	9.65e-07	9.94e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TP53—urinary bladder cancer	9.62e-07	9.92e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PPARG—urinary bladder cancer	9.54e-07	9.83e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MYC—urinary bladder cancer	9.41e-07	9.7e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—EP300—urinary bladder cancer	9.32e-07	9.6e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PPARG—urinary bladder cancer	9.31e-07	9.59e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—KRAS—urinary bladder cancer	9.3e-07	9.59e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—HRAS—urinary bladder cancer	9.23e-07	9.51e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—EGFR—urinary bladder cancer	9.2e-07	9.48e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—HRAS—urinary bladder cancer	9.2e-07	9.48e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	9.16e-07	9.44e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	9.16e-07	9.44e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—SRC—urinary bladder cancer	9.06e-07	9.34e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CREBBP—urinary bladder cancer	8.94e-07	9.21e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PPARG—urinary bladder cancer	8.77e-07	9.04e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	8.71e-07	8.97e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PPARG—urinary bladder cancer	8.69e-07	8.96e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—KRAS—urinary bladder cancer	8.69e-07	8.96e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TP53—urinary bladder cancer	8.67e-07	8.93e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTEN—urinary bladder cancer	8.66e-07	8.92e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTEN—urinary bladder cancer	8.46e-07	8.72e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	8.42e-07	8.68e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	8.4e-07	8.66e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	8.35e-07	8.61e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—HRAS—urinary bladder cancer	8.29e-07	8.54e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TP53—urinary bladder cancer	8.27e-07	8.52e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—EP300—urinary bladder cancer	8.26e-07	8.51e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MYC—urinary bladder cancer	8.12e-07	8.37e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—TYMS—urinary bladder cancer	8.09e-07	8.34e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—EP300—urinary bladder cancer	8.07e-07	8.32e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	8e-07	8.25e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	8e-07	8.25e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—EGFR—urinary bladder cancer	7.94e-07	8.19e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—HRAS—urinary bladder cancer	7.91e-07	8.15e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TP53—urinary bladder cancer	7.73e-07	7.96e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GPX1—urinary bladder cancer	7.66e-07	7.9e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	7.52e-07	7.75e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—KRAS—urinary bladder cancer	7.5e-07	7.73e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	7.5e-07	7.73e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PPARG—urinary bladder cancer	7.43e-07	7.66e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—HRAS—urinary bladder cancer	7.39e-07	7.61e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTEN—urinary bladder cancer	7.33e-07	7.55e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTGS2—urinary bladder cancer	7.32e-07	7.54e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	7.14e-07	7.36e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	7.07e-07	7.29e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—EP300—urinary bladder cancer	6.99e-07	7.2e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	6.9e-07	7.11e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	6.84e-07	7.05e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TP53—urinary bladder cancer	6.67e-07	6.87e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTEN—urinary bladder cancer	6.54e-07	6.74e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTEN—urinary bladder cancer	6.38e-07	6.58e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HRAS—urinary bladder cancer	6.38e-07	6.57e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—EP300—urinary bladder cancer	6.24e-07	6.43e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—EP300—urinary bladder cancer	6.09e-07	6.27e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTEN—urinary bladder cancer	6.02e-07	6.2e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTEN—urinary bladder cancer	5.96e-07	6.15e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	5.84e-07	6.02e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—EP300—urinary bladder cancer	5.74e-07	5.91e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PPARG—urinary bladder cancer	5.73e-07	5.91e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—EP300—urinary bladder cancer	5.69e-07	5.86e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	5.51e-07	5.68e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTEN—urinary bladder cancer	5.1e-07	5.25e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—EP300—urinary bladder cancer	4.86e-07	5.01e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	4.51e-07	4.65e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTEN—urinary bladder cancer	3.93e-07	4.05e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—EP300—urinary bladder cancer	3.75e-07	3.87e-06	CbGpPWpGaD
